Research News
The GLP-1 market is about to get significantly more competitive, and the mechanism of that competition may redefine ...
The single biggest barrier to peptide adoption has never been efficacy or even cost — it’s the needle. ...
We’ve known for a while that tirzepatide produces superior weight loss compared to other GLP-1 medications. The question ...
In February and April 2026, the regulatory landscape for compounded peptides shifted significantly. HHS Secretary Robert F. Kennedy ...
Mark your calendar: July 23–24, 2026. That’s when the FDA’s Pharmacy Compounding Advisory Committee (PCAC) convenes to review ...
The debate between tirzepatide and semaglutide has dominated GLP-1 conversations for three years. Anecdotes, clinical trials, and forum ...
Humanin is a mitochondria-derived peptide that has attracted growing scientific attention since its initial characterization in 2001 from ...
Three years after regulatory approval, tirzepatide’s real-world performance data is now substantial — and the Phase IV evidence ...
A new publication in Rejuvenation Research presents what researchers are calling the longest-running observational follow-up of a human ...
GHK-Cu — a naturally occurring copper-binding peptide (glycine-histidine-lysine) — has been studied for decades in skin science, but ...
Latest News
